Inovio Pharmaceuticals Inc. (NASDAQ:INO) went down by -10.90% from its latest closing price compared to the recent 1-year high of $10.33. The company’s stock price has collected -20.47% of loss in the last five trading sessions. The Wall Street Journal reported on 09/28/20 that Inovio Covid-19 Vaccine Trial Placed on Hold After FDA Questions
Is It Worth Investing in Inovio Pharmaceuticals Inc. (NASDAQ :INO) Right Now?
Plus, the 36-month beta value for INO is at 0.79. Opinions of the stock are interesting as 2 analysts out of 8 who provided ratings for Inovio Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 6 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $9.57, which is $7.2 above the current price. INO currently public float of 207.00M and currently shorts hold a 21.92% ratio of that float. Today, the average trading volume of INO was 4.55M shares.
INO’s Market Performance
INO stocks went down by -20.47% for the week, with a monthly drop of -30.29% and a quarterly performance of -37.63%, while its annual performance rate touched -64.47%. The volatility ratio for the week stands at 8.44% while the volatility levels for the past 30 days are set at 6.94% for Inovio Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -20.59% for INO stocks with a simple moving average of -58.64% for the last 200 days.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with BofA Securities repeating the rating for INO by listing it as a “Neutral.” The predicted price for INO in the upcoming period, according to BofA Securities is $10 based on the research report published on January 21st of the current year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see INO reach a price target of $6, previously predicting the price at $8. The rating they have provided for INO stocks is “Hold” according to the report published on December 29th, 2021.
BofA Securities gave a rating of “Underperform” to INO, setting the target price at $8 in the report published on September 10th of the previous year.
INO Trading at -27.55% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.06% of loss for the given period.
Volatility was left at 6.94%, however, over the last 30 days, the volatility rate increased by 8.44%, as shares sank -27.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.40% lower at present.
During the last 5 trading sessions, INO fell by -20.47%, which changed the moving average for the period of 200-days by -71.10% in comparison to the 20-day moving average, which settled at $2.94. In addition, Inovio Pharmaceuticals Inc. saw -52.51% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at INO starting from BENITO SIMON X, who sale 2,000 shares at the price of $3.16 back on Mar 16. After this action, BENITO SIMON X now owns 57,305 shares of Inovio Pharmaceuticals Inc., valued at $6,320 using the latest closing price.
Weiner David B., the Director of Inovio Pharmaceuticals Inc., sale 4,083 shares at $3.20 during a trade that took place back on Mar 14, which means that Weiner David B. is holding 883,625 shares at $13,066 based on the most recent closing price.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -17535.79 for the present operating margin
- -166.56 for the gross margin
The net margin for Inovio Pharmaceuticals Inc. stands at -17109.87. Equity return is now at value -62.50, with -53.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.82.